TOPICOP©: A New Scale Evaluating Topical Corticosteroid Phobia among Atopic Dermatitis Outpatients and Their Parents
Open Access
- 16 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e76493
- https://doi.org/10.1371/journal.pone.0076493
Abstract
The fear of using topical corticosteroids, usually called topical corticophobia, is a frequent concern for atopic dermatitis patients and/or their parents. Assessing patients’ atopic dermatitis and their parents’ topical corticosteroid phobia is an essential step to improving adherence to treatment. Because topical corticophobia appears to be a complex phenomenon, its evaluation by binary responses (yes/no) is too simplistic. Thus, a scale is needed, which is capable of identifying the subtleties of topical corticosteroid phobia. To develop and validate a scale, TOPICOP©, measuring worries and beliefs about topical corticosteroids among atopic dermatitis outpatients and their parents. An initial statistical validation of TOPICOP was carried out, collecting qualitative data about patients’ topical corticophobia behaviors and beliefs using focus-group methodology. Then, 208 outpatients or their parents from five French centers completed a self-administered questionnaire built from focus-group results. The scale-development process comprised an explanatory principal component analysis, Cronbach’s α-coefficients and structural equation modeling. The validated questionnaire comprised 12 items, covering two important dimensions relative to “worries” (6 items) and “beliefs” (6 items). Psychometric properties showed that items had very good communality (>0.60) within their own dimension. The final two-factor solution accounted for 47.3% of the variance. Cronbach’s α-coefficients were, respectively, 0.79 and 0.78. Structural equation modeling strongly supported the possibility of calculating a global score. TOPICOP© is the first scale aimed at assessing topical corticophobia in adult patients and parents of children with eczema. TOPICOP® has excellent psychometric properties and should be easy to use in everyday clinical practice for clinicians and researchers. Further studies are needed to confirm our results and validate TOPICOP© in other cultures.Keywords
This publication has 30 references indexed in Scilit:
- Harmonising Outcome Measures for Eczema (HOME).Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, GermanyBritish Journal of Dermatology, 2010
- Steroid fears in children with eczemaActa Paediatrica, 2006
- The Burden of Atopic Dermatitis: Impact on the Patient, Family, and SocietyPediatric Dermatology, 2005
- Burden of Atopic dermatitis in CanadaInternational Journal of Dermatology, 2004
- Why Do Patients with Atopic Dermatitis Refuse to Apply Topical Corticosteroids?Dermatology, 2000
- The family impact of childhood atopic dermatitis: the Dermatitis Family Impact questionnaireBritish Journal of Dermatology, 1998
- Steroid scare.Archives of Disease in Childhood, 1987
- A general method for analysis of covariance structuresBiometrika, 1970
- Convergent and discriminant validation by the multitrait-multimethod matrix.Psychological Bulletin, 1959
- Coefficient alpha and the internal structure of testsPsychometrika, 1951